SEC Form 4 · accession 0000874015-16-000148

IONIS PHARMACEUTICALS INC · IONS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

B Lynne Parshall

Officer — COO · Director

Period of report

Dec 1, 2016

Accepted (ET)

Dec 2, 2016 · 6:58 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000874015

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Dec 1, 2016	M	7,000	$14.69	A	23,693	D
Common Stock^F1,F2	Dec 1, 2016	S	7,000	$41.49	D	16,693	D
Common Stock^F1	Dec 1, 2016	M	5,500	$14.69	A	22,193	D
Common Stock^F1,F3	Dec 1, 2016	S	5,500	$43.17	D	16,693	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F4	$14.69	Dec 1, 2016	M	12,500	D	Jan 2, 2014	Jan 29, 2020	Common Stock	12,500	12,410	D

Explanation of responses

F1Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $42.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.60 to $43.50, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F4Grant of 1/30/2013 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/2014. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 15,570 shares per year. Following this transaction, the option was exercisable as to 9,815 on 12/1/2016.